The Dental Roll-Up DSO Playbook (2026): How to Build a Dental Group

Last updated: August 2026

I'm Sean Yu, co-founder of Peony. Before Peony I spent my career on the deal side, and the dental roll-up is one of the most misunderstood machines in the middle market. From the outside it looks like a simple money-printer: buy solo practices cheap, staple them together, sell the stack for a fat multiple. From the inside it is a legal structure that has to thread a doctrine most people have never heard of, an acquisition process that has to repeat cleanly dozens of times, and an integration problem that quietly destroys value if you rush it. This is the buyer's playbook, end to end: why dental is still consolidating and how far, the multiple-arbitrage math and its honest caveats, how to build the DSO/MSO structure legally, where add-ons come from and at what cadence, how to structure each acquisition from the buyer's side, what breaks in integration, how to finance the whole thing, and what the exit actually is. I run Peony, a data room company serving 6,800+ customers, so I have a specific view on the confidential-process tooling a serial acquirer needs, and I'll get to it, but most of what follows is about the deal, not the software.

Quick answer. A dental roll-up buys solo practices at roughly 5x to 7x adjusted EBITDA (per advisory bands) and aims to sell the assembled platform at roughly 10x to 12x or more — that spread is the model. It runs on a DSO/MSO structure: a licensed dentist owns the clinical PC, a separately owned management company owns everything non-clinical, joined by a management services agreement, because the corporate practice of dentistry doctrine bars non-dentist control of care. DSO affiliation reached 16.1% of U.S. dentists in 2024 per the ADA, and more than 1 in 4 early-career dentists are affiliated, so the runway is real, though how far consolidation goes is genuinely contested. Each acquisition typically runs 60% to 80% cash, 15% to 40% rollover equity, and an earnout, with a 2-to-5-year work-back. The exit is a recapitalization after a 3-to-7-year hold, where the closed diligence files from every add-on become the sell-side evidence.

What is a dental roll-up, and why is dental still consolidating?

A dental roll-up is the serial acquisition of independent practices into a single group that shares management infrastructure, and dental is still consolidating because most practices are still independently owned, the model has a real cost advantage at scale, and a generational ownership shift is feeding supply. The buyer, almost always a dental service organization (DSO), assembles many small practices into something an institutional buyer will pay a platform multiple for. To underwrite that thesis you have to be honest about how far consolidation has actually gone, because the number people quote at conferences is usually wrong.

Start with the one figure that is well sourced. Per the ADA Health Policy Institute, 16.1% of U.S. dentists were affiliated with a DSO in 2024, more than double the roughly 7.2% of 2015, as reported by DentistryIQ. The HPI defines "affiliated" as an outside entity managing some or all non-clinical functions. Among younger dentists the trend is much stronger: more than 1 in 4 (over 25%) dentists up to 10 years out of dental school were affiliated with a DSO in 2024, per ADA News, with far lower affiliation among long-established dentists; the underlying HPI workforce data shows Colorado and Oklahoma with the largest recent increases. The generational split matters to a buyer: new dentists carry more student debt and increasingly prefer employment to ownership, which both feeds associate pipelines and, over time, feeds practices to market when older owners retire without an internal successor.

Where consolidation goes from here is where you should be skeptical of anyone selling certainty. On the bullish side, Brian Colao, who directs Dykema's DSO Industry Group, predicts that 75% to 80% of dental practices will be consolidated in 10 to 15 years. On the skeptical side, CPA Brian Hanks estimates that strict-definition consolidation never gets above 20% of all dental practices, per the same DentistryIQ analysis. Both are looking at real data and defining "consolidated" differently, and the "dentistry is 35% consolidated" line you'll see repeated is a contested, metric-ambiguous number I would not underwrite against. Narrowing to private equity specifically, PE affiliation roughly doubled from 6.6% in 2015 to 12.8% in 2021 per a Health Affairs study cited in the same analysis. The honest read for a buyer: dentistry is consolidating meaningfully, but it is still overwhelmingly owned by independent dentists, and that un-acquired majority is precisely the supply that makes a roll-up possible.

One more thing you should underwrite against, not around: the recent market has been choppier than the froth of a few years ago. Dykema characterized 2025 as "The Year of the Muted Recovery": the post-rate-cut M&A rebound many expected largely failed to materialize as rates stayed high, tariffs bit, and healthcare-fraud enforcement spiked, and over 50 significant DSO sale processes had been abandoned during the downturn that began in mid-2022. And yet appetite is returning on the buy side: 69% of DSOs said their private-equity sponsors expect a moderate or high increase in 2026 acquisition activity, per TUSK Practice Sales' Q2 2026 Dental Market Report. Note the population there is DSOs and their sponsors, not dental groups broadly. The takeaway is that consolidators want to buy, but they are choosier and their diligence is harder, which raises the bar on execution for anyone building a group today.

What is the multiple-arbitrage math?

The model is multiple arbitrage: buy small practices at low-single-digit-to-mid multiples, assemble them into a platform an institutional buyer values at a double-digit multiple, and capture the spread — but the spread is not free money, because integration cost, retrade risk, and illiquid rollover equity all narrow it. This is the single most important idea in the roll-up, and also the one most likely to be oversold, so let me give it to you with the caveats attached.

Here is the arbitrage in its simplest form, with every band attributed. On the buy side, single-doctor and small tuck-in practices trade at roughly 5x to 7x adjusted EBITDA, with the smallest solo tuck-ins in the low-to-mid single digits, per Deal Prospectors' 2026 EBITDA-by-size analysis; Auxo Capital Advisors' 2026 guide pegs single-location DSO tuck-ins even lower, nearer 3.5x to 5.5x. As those practices roll up, the same source puts associate-led groups (roughly 1 to 3 million dollars of EBITDA) at about 7x to 9x, emerging multi-location platforms (3 to 5 million dollars) at about 9x to 11x, and platform-grade DSO groups (5 million dollars-plus) at about 10x to 12x or higher. The spread between what you pay for a solo practice and what a buyer pays for the assembled platform is the return engine. Scale itself creates value, because a portfolio diversifies the single-practice key-person and local-market risk that institutional capital will pay up to smooth, per Auxo.

Now the caveats, because a spread on a slide is not a spread in a bank account. First, integration cost is real and front-loaded: the same platform that commands 11x has to actually deliver the centralized billing, purchasing, and management that justify it, and that infrastructure costs money and management attention before it pays back. Second, retrade risk sits on every single buy. The most common cause of a post-LOI price cut is aggressive or unsupportable EBITDA add-backs; a buyer's quality-of-earnings review can strip meaningful dollars off an over-claimed number. To put the mechanics in concrete but illustrative terms: if a seller claims 1.1 million dollars of adjusted EBITDA but can document only 800,000 dollars, the 300,000 dollars struck is, at a 6x multiple, 1.8 million dollars of purchase price gone. Provider concentration, messy financials, short leases, compliance gaps, and credentialing delays drive retrades and delays too, per Dental Practice Insider and Dental Transitions. Third, the arbitrage narrows when rates bite, which is exactly what the muted-recovery data above describes: higher debt cost compresses both the multiple you can pay and the multiple you can exit at, and a spread that looked comfortable at low rates can thin out fast. The arbitrage is genuine, but it rewards operators who can integrate and underwrite, not financial engineers counting on the multiple gap alone.

How do you structure a DSO legally?

You build a two-entity structure because the corporate practice of dentistry doctrine bars non-dentists and corporations from owning or controlling clinical practices: a licensed dentist owns the professional entity that delivers care, and a separately owned management services organization owns everything non-clinical, joined by a management services agreement. This is the load-bearing wall of the whole model, and it is state-specific enough that you build it with healthcare counsel rather than from any template, including this one.

Start with the doctrine. As a national principle, non-dentists and corporations generally may not own or control clinical dental practices or clinical decision-making — dentistry must be delivered by licensed dentists, per Hendershot Cowart P.C. The DSO model is the lawful workaround: the clinical side lives in a professional entity (a PC or PLLC) owned by a licensed dentist, often called the "friendly PC," which employs the dentists and hygienists and holds the clinical authority. The non-clinical side lives in the management services organization (the MSO, used more or less interchangeably with "DSO" in the industry), which can be owned by non-dentists and private-equity capital. The MSO owns or leases the real estate, equipment, and systems, and provides billing, marketing, HR, procurement, IT, and administration.

The document that connects them is the management services agreement (MSA), and three parts of it deserve your attention as a buyer. The scope of services defines exactly what the MSO provides and, just as importantly, what it does not touch, because clinical judgment has to remain with the licensed dentists to respect the doctrine. The fee structure sets how the MSO is paid — commonly a management fee, structured to be defensible as fair-market value for services rendered rather than a device for a non-dentist to capture the practice's clinical profit. And the term governs how long the arrangement runs and how it unwinds. Get the fee structure and control provisions wrong and you don't have an aggressive structure, you have an unlawful one.

The doctrine varies substantially by state, which is the part that turns a national playbook into fifty separate legal problems. California strengthened its restrictions when Governor Newsom signed SB 351, effective January 1, 2026, formalizing limits on private-equity- and hedge-fund-operated dentist and physician management platforms and their control over clinical decisions, per Sidley Austin. Texas bars non-dentist control of dental treatment while statutorily accommodating dental service organizations for the management side, per Rapp & Krock. Colorado has enacted stricter regulations over DSO involvement amid corporate-practice concerns, per DDS Lawyers. I am naming states, not statute sections, deliberately: the specifics move and are exactly what your counsel is for. If you plan to acquire across state lines, the CPOD map is a gating input to your geography, not an afterthought.

Where do add-ons come from, and what does the cadence look like?

Add-ons come from three main channels — dental transition brokers and advisory firms, direct outreach to owners, and your own associate pipeline — and the discipline that separates a real consolidator from a hobbyist is running acquisitions as a repeatable cadence rather than one heroic deal at a time. Sourcing is a pipeline problem, and the buyers who win treat it like one.

The channels, in rough order of volume for most groups. Transition brokers and dental M&A advisors run organized sale processes and bring you practices that are already at least somewhat prepared; you pay for that in price and competition, since a brokered deal is often a limited auction. Direct outreach to owners who are not formally on the market is slower and more relationship-driven, but it is where you find the off-market practice at a fair multiple without an auction premium — this is the grind that builds proprietary deal flow. And your associate pipeline doubles as a sourcing engine: associates you employ know which nearby owners are thinking about retiring, and an associate who wants to keep equity can become the clinical anchor of a newly acquired location. For choosing the advisors and brokers who run these processes, our roundup of the best dental M&A advisors is the place to start.

The cadence is what most people underestimate. The quiet consolidators in this market are not doing one splashy deal a year; the busiest are running 20 to 30 partnerships a year, and at that pace acquisition is a production line, not a project. That is the lesson I keep coming back to from the generic serial-acquisition side of my work: a firm buying at that cadence cannot rebuild its diligence process from scratch each time, so it runs a room-per-target program off a shared, reusable index — one standing platform room, a separate diligence room per practice, and standing rooms for the money — where roughly 80% of the request list is identical deal to deal and each new room stages in an afternoon rather than getting rebuilt. That is the entire argument of our roll-up data room guide, and it applies directly at dental scale; I won't restate its full room architecture here, but the cadence discipline it describes is exactly what a dental consolidator needs. For the per-practice screen itself — what to actually diligence on each dental target before you sign — route to our dental due diligence checklist, which covers the practice-level financial, clinical, and compliance review in depth.

How do you structure each acquisition?

A typical DSO acquisition of a practice runs roughly 60% to 80% cash at close, 15% to 40% in rollover equity, and the remainder in earnouts, with the selling dentist committing to a 2-to-5-year work-back and a base of roughly $200,000 to $400,000 plus production — and the whole structure is engineered to keep the person whose relationships are the goodwill. These are advisory-firm norms, not universal rules, but they describe the shape of nearly every deal you'll structure from the buyer's side.

Take the consideration mix first. Per Deal Prospectors and Scott Leune's DSO acquisition framework, a deal is commonly 60% to 80% cash at close, 15% to 40% rollover or retained equity (most DSOs require the seller to reinvest roughly 10% to 30% of proceeds into acquirer equity), and the balance in earnouts tied to production or retained-EBITDA targets over 12 to 36 months, 24 months being most common. Only the cash at close is guaranteed. The rollover equity is the "second bite at the apple": positioned as upside if the DSO recapitalizes or sells at a higher multiple in roughly 3 to 7 years, but illiquid for years and tied to the whole platform's performance rather than the individual practice, per Dental Wealth Partners. As a buyer you should be candid with sellers about that illiquidity, because a seller who feels misled about their rollover is a retention problem waiting to happen.

The equity can be structured two ways, and the choice shapes both alignment and complexity. In the holdco model, the seller rolls into the parent DSO's equity, so their upside is tied to the entire platform. In the joint-venture (JV) model, the seller retains equity at the subsidiary or practice level, keeping a more direct line to the performance they influence; Specialty1 Partners uses a JV model explicitly, and it tends to appeal to specialists who want to feel ownership of their own P&L. Looking across the larger consolidators shows both patterns in the wild: MB2 Dental built an 800-plus-practice group (roughly, as of 2025) around a doctor-equity model, while the biggest platforms like Heartland Dental (roughly 1,900-plus supported offices, as of 2025) and Aspen Dental (1,000-plus offices, roughly, as of 2025) run at holdco scale. The right model depends on whether your sellers are GPs or specialists, and on how much direct operational autonomy you intend to leave in place.

Then the human terms, which are the retention machine. The selling dentist typically commits to a work-back of roughly 2 to 5 years (many DSO work-backs carry a five-year minimum), with full integration to the platform model usually over the first 12 to 24 months post-close, per Dental Transitions. Post-sale compensation typically runs a base of roughly $200,000 to $400,000 plus production bonuses, often expressed as a percentage of collections, per Deal Prospectors. Understand what all of this is doing: rollover equity, the earnout, and the work-back together bind the selling dentist to the practice's continued performance, because in a service business the goodwill you bought walks on two legs. Structure the retention badly and you have overpaid for a practice that leaves with its owner. If you want to see this same deal from the other side of the table — how the selling dentist reads your offer — our DSO offer evaluation guide is the seller's read of exactly these structures, and it's worth understanding what your counterparty is thinking.

What breaks in integration?

Integration is where dental roll-ups quietly lose the value they paid for, and the usual culprits are credentialing and payer-enrollment lag, PPO contract migration, staff and associate retention, and a slipping hygiene department — none of them strategic, all of them operational, and all of them best contained by a disciplined first-100-days plan. The deal closes on a spreadsheet; the value is realized or destroyed in the plumbing.

The first thing that breaks is credentialing and payer enrollment. A change of ownership can trigger re-credentialing of providers with payers and a change-of-ownership process on payer contracts, and reimbursement can stall until it clears. The practical effect is a cash-flow dip immediately after close, on an otherwise healthy practice, purely because the paperwork lags the deal — so you underwrite working capital for it rather than getting surprised by it. Closely related is PPO contract migration: fee schedules and network participation do not port cleanly, and this is a live margin issue, since industry consultants (PPO-negotiation vendors, so read the incentive) report average PPO write-offs commonly landing around 40% to 60% of billed fees, with reimbursement essentially flat through 2025 while overhead rose, per Veritas Dental Resources. Migrating a practice onto better-negotiated contracts is one of the real operating levers a DSO has, but it takes time and specialist attention.

Then the people. Staff and associate retention is the risk that a service business runs entirely on the humans who deliver the service; if front-desk staff, hygienists, or associate dentists leave during the transition, you inherited a thinner practice than you bought. The single best operating KPI to watch here is the hygiene department, which contributes roughly 25% to 33% of total practice production in a healthy practice (a baseline near 25%, high performers at 30% to 33%), per Dentx. A hygiene program that slips after close is an early warning that the recare system is breaking under the transition — patients aren't being rebooked, or a departed hygienist took a book of recurring visits with them. Watch hygiene production weekly in the first quarter; it moves before the P&L does.

Underneath all of it sits the centralize-versus-local trade-off, which has no universal answer. Centralizing billing, procurement, marketing, and scheduling is where the synergies live, but push standardization too hard or too fast and you erode the local relationships and clinical autonomy you paid a goodwill premium for. The workable pattern is a first-100-days plan that sequences the back-office consolidation aggressively (billing, purchasing, IT, HR) while moving deliberately on anything patient-facing or clinical, and that assigns a named integration owner rather than letting the deal team roll off to the next target and leave integration to an inbox. The healthcare-specific diligence framework that feeds this plan lives in our healthcare due diligence guide; the integration checklist is what you build from it.

How do you finance a dental roll-up?

A dental roll-up is financed with a stack that changes as it scales: early add-ons can run on SBA and practice-lender debt, but the $5 million SBA cap forces platforms to graduate to conventional bank debt, unitranche, or private credit, while the equity comes from one of three sources — a PE-backed platform, an independent sponsor, or a doctor-funded group. The financing shape at three practices is not the financing shape at thirty, and planning the transition is part of the underwriting.

Take debt first. Early on, a dental buyer has access to the same favorable lending that individual dentists enjoy, because dental is a historically low-default category. SBA 7(a) loans cap at $5 million, offer terms up to 10 years (up to 25 if commercial real estate is included), can finance goodwill and intangibles, and are commonly available at up to 100% financing to strong-credit buyers with clean practice books, per the Dental Practice Loan Guide and Dental Practice Insider. The lenders active in this space are worth knowing by name: Bank of America Practice Solutions offers dental acquisition, equipment, and relocation loans up to 5 million dollars; Provide is a Fifth Third Bank company financing dental, medical, and veterinary practices; and Panacea Financial is a division of Primis Bank with an ADA Member Advantage endorsement. But that $5 million cap is exactly why a roll-up graduates: once acquisitions accumulate, the group outgrows SBA and moves to conventional bank facilities, unitranche, or a private-credit delayed-draw term loan committed at the platform close and drawn add-on by add-on. On rates, be careful with any fixed number — SBA 7(a) variable rates are priced at Prime plus a spread of roughly 1.5% to 2.75%, per Bay Street Lending, so the effective rate moves with Prime rather than sitting where a given month's quote put it.

On the equity side, there are three models, and which one you are determines almost everything about how you operate. A PE-backed platform brings institutional capital and a mandate to build fast toward a recapitalization, with the discipline (and the pressure) that private-equity ownership implies. An independent sponsor raises capital deal by deal rather than from a committed fund, which trades certainty of capital for flexibility and a different economics split; the general independent-sponsor-in-healthcare path is covered in our independent sponsor healthcare guide. And a doctor-funded group compounds off its own cash flow and reinvested proceeds, growing more slowly but keeping clinical control and equity in dentists' hands. There is no universally right choice; there is only the choice that matches your capital access, your growth ambition, and how much control you are willing to give up to move faster.

What does the exit look like?

The exit for a dental DSO is usually a recapitalization rather than an outright sale: after a hold of roughly 3 to 7 years, the platform sells a majority stake to a larger PE buyer or bigger DSO at a materially higher multiple than it paid for its practices, and the sponsor plus any dentists who rolled equity take a second bite. This is the moment the multiple arbitrage from the second section is actually realized, and it is a documentation-heavy event that rewards the buyer who kept clean records from the very first add-on.

The pattern is visible across the larger platforms, and the honest way to present it is with "as of" hedges, because ownership in this market is fluid. MB2 Dental completed a recapitalization with new investor Warburg Pincus in November 2024, in a roughly $525 million transaction that valued the group near $3.5 billion and brought Warburg in alongside existing investors Charlesbank Capital Partners and KKR, per Warburg Pincus. Smile Brands has been owned by Gryphon Investors since 2016 (acquired from prior owner Welsh, Carson, Anderson & Stowe), and its 2023 transaction was a dividend recapitalization, not a change of control, per Gryphon Investors. Heartland Dental, the largest U.S. DSO, has been majority-owned by KKR since 2018, with Ontario Teachers' Pension Plan holding a minority position, per Group Dentistry Now. Each of these is a liquidity event on a platform assembled from many smaller practices, and each recap is where rolled-over dentists find out whether their second bite paid.

Here is the part that connects the exit back to everything before it. The recap is run out of a dedicated data room, and the buyer's first structural question is whether the practices that built the group were bought well — which is answered not with a narrative but with the closed diligence rooms from every add-on: consistent taxonomy, intact Q&A threads, disclosure schedules, per-page audit trails. The consolidators that keep every add-on room find their sell-side vendor diligence largely assembles itself at exit; the ones that let rooms die at each closing pay twice, once in advisor hours reconstructing history and once in price when reconstructed history reads weaker than recorded history. The recapitalization event itself — how to stage that room and what a recap buyer expects — is its own subject, and our DSO recapitalization data room guide covers it in depth. The through-line of this entire playbook is that the exit is won at the first acquisition, not the last.

Frequently asked questions

What is a dental roll-up and how does a DSO make money?

A dental roll-up is the serial acquisition of dental practices into a single group that shares management, purchasing, and administrative infrastructure. The consolidator, usually organized as a dental service organization (DSO), makes money three ways: multiple arbitrage (buying solo practices at roughly 5x to 7x adjusted EBITDA per advisory bands and selling the assembled platform at roughly 10x to 12x or more), operating leverage (spreading billing, marketing, HR, and procurement across many practices), and a second-bite recapitalization several years out. The DSO owns only the non-clinical management side under a management services agreement; licensed dentists own the clinical practice, because the corporate practice of dentistry doctrine bars non-dentist control of clinical care. The arbitrage is real but not free money: integration costs, retrade risk, and rollover equity that is illiquid for years all eat into the headline spread.

How consolidated is the dental industry in 2026?

Less than headlines suggest, and the honest answer is that it depends on how you count. Per the ADA Health Policy Institute, 16.1% of U.S. dentists were affiliated with a DSO in 2024, more than double the roughly 7.2% of 2015. Among newer dentists the shift is sharper: more than 1 in 4 (over 25%) dentists up to 10 years out of dental school were DSO-affiliated in 2024. Where it goes from here is genuinely contested. Brian Colao of Dykema's DSO Industry Group predicts 75% to 80% of practices will be consolidated in 10 to 15 years, while CPA Brian Hanks estimates strict-definition consolidation never gets above 20% of all practices. Private-equity affiliation specifically roughly doubled from 6.6% in 2015 to 12.8% in 2021 per a Health Affairs study. So dentistry is consolidating meaningfully but is still mostly owned by independent dentists, and the runway of un-acquired practices is exactly what makes the roll-up thesis work.

How do you structure a DSO legally?

You split the business in two because the corporate practice of dentistry (CPOD) doctrine bars non-dentists and corporations from owning or controlling clinical practices or clinical decisions. A licensed dentist owns the professional entity (a PC or PLLC) that employs the clinicians and delivers care, and a separately owned management services organization (the MSO, often used interchangeably with DSO) owns everything non-clinical: billing, marketing, HR, procurement, real estate, IT, and administration. The two are joined by a management services agreement (MSA) that sets the scope of management services, the management fee, and the term. The doctrine varies substantially by state. California formalized restrictions on private-equity-operated dentist management platforms in SB 351, effective January 1, 2026; Texas bars non-dentist control of treatment while statutorily accommodating dental service organizations for the management side; Colorado has enacted stricter DSO regulations. This is architecture you build with healthcare counsel in your states, not from a template.

How does a DSO structure each practice acquisition?

A typical DSO acquisition of a practice runs roughly 60% to 80% cash at close, 15% to 40% in rollover or retained equity, and the remainder in earnouts tied to performance over 12 to 36 months (24 months is most common), per advisory-firm norms. The rollover equity is positioned as a second bite at the apple if the DSO recapitalizes at a higher multiple in roughly 3 to 7 years, but it is illiquid for years and tied to the whole platform's performance, not the selling practice. Equity is structured either as holdco equity (the seller rolls into the parent DSO) or as a joint venture at the practice or subsidiary level, a model consolidators like Specialty1 Partners use explicitly. The selling dentist usually commits to keep practicing for a work-back period commonly cited at 2 to 5 years, with a base of roughly $200,000 to $400,000 plus production bonuses. Rollover plus work-back is how a buyer keeps the person whose relationships are the goodwill it just bought.

What breaks in dental roll-up integration?

The operational plumbing breaks before the strategy does. Credentialing and payer enrollment lag is the classic one: a change of ownership can require re-credentialing providers and re-papering PPO contracts, and payments stall until it clears, so cash flow dips right after close even when the practice is healthy. PPO contract migration is its own project because reimbursement carries over unevenly, and industry consultants report average PPO write-offs commonly landing around 40% to 60% of billed fees. Staff and associate retention is the human risk, since the people who deliver care can leave. The hygiene department is the operating KPI to watch, contributing roughly 25% to 33% of production in a healthy practice; a slipping hygiene program signals the recare system is breaking under the transition. And every centralize-versus-local decision (scheduling, purchasing, clinical autonomy) is a trade-off between synergy and the local goodwill you paid for. A disciplined first-100-days plan is what keeps these from compounding.

How do you finance a dental roll-up?

Financing changes shape as you scale. Early add-ons often run on the same tools an individual dentist uses: SBA 7(a) loans (capped at $5 million, terms up to 10 years or 25 with real estate, able to finance goodwill), from lenders active in dental such as Bank of America Practice Solutions, Provide (a Fifth Third company), and Panacea Financial (a division of Primis Bank). But the $5 million SBA cap is exactly why platforms graduate: once acquisitions stack up, a roll-up moves to conventional bank debt, unitranche, or a private-credit facility, frequently a delayed-draw term loan committed at the platform close and drawn add-on by add-on. On the equity side, the three models are a PE-backed platform, an independent sponsor raising deal by deal, and a doctor-funded group compounding off cash flow. SBA rates are priced at Prime plus a spread of roughly 1.5% to 2.75%, so the effective rate moves with Prime rather than sitting at a fixed number.

What does the exit look like for a dental DSO?

The exit is usually a recapitalization, not an outright sale, and it is where the arbitrage is actually realized. After a hold of roughly 3 to 7 years, a platform sells a majority stake to a larger private-equity buyer or a bigger DSO at a materially higher multiple than it paid for its practices, and the sponsor plus any dentists who rolled equity take a second bite. The recent record shows the pattern: MB2 Dental completed a recapitalization with new investor Warburg Pincus in November 2024; Smile Brands has been owned by Gryphon Investors since 2016 and did a dividend recapitalization in 2023; Heartland Dental has been majority-owned by KKR since 2018. Each of these is a liquidity event on a platform assembled from many smaller practices. The recap is a documentation-heavy event in its own right, run out of a dedicated data room, and it is the moment the closed diligence files from every add-on become the sell-side evidence base.

What data room setup does a dental roll-up need?

A dental roll-up needs a program of rooms, not one room: a standing platform room for corporate and financing records, a separate diligence room for each practice you acquire, an integration room that receives each deal after close, and standing rooms for lenders and LPs. The reason is isolation and evidence: each seller's data stays walled off from the others, and every closed room becomes exit evidence at the recap. Because a consolidator underwrites the same kind of practice repeatedly, most of the request list is identical deal to deal, so each new room clones from a template in an afternoon. On flat per-admin pricing this stops scaling with deal count. At Peony, a data room company serving 6,800+ customers, the Deal Team plan runs $64 per admin per month billed annually (minimum four admins, or $89 monthly) and covers unlimited rooms; a solo independent sponsor on the Data Room plan pays $52 per admin per month billed annually ($75 monthly) for the same unlimited-rooms coverage with per-viewer watermarking and Advanced NDA gating. Simple NDA gating and one-click revoke start on the $30 Business plan ($44 monthly), analytics and link expiry are on every tier including Free, and viewers are always free, so a full lender syndicate adds nothing to the bill.

---

About the author: Sean Yu is the co-founder of Peony, the data room platform used by 6,800+ customers across M&A, fundraising, and diligence workflows — including healthcare operators and dental groups running serial-acquisition programs. Before Peony, Sean spent his career on the deal side — M&A at Nomura, early-stage VC at Backed VC, and growth-equity / secondaries at Target Global — running and supporting sell-side and buy-side processes across healthcare, software, and industrials in North America and Europe. He studied Biomedical Engineering at Imperial College London on a full scholarship before dropping out to build companies. Sean is also a co-founder of Gingercontrol, an AI-native trade-compliance platform that raised $2.1M. Contact: sean@peony.ink • LinkedIn.

Sources

• ADA News — HPI: More new dentists affiliated with DSOs (Nov 2025)
• DentistryIQ — Is dentistry really 35% consolidated? Let's check the math (Aug 2026)
• Dykema — DSO Industry Group practice page
• Dykema — DSO M&A Sector Spotlight, 2025 Annual M&A Outlook
• TUSK Practice Sales — Q2 2026 Dental Market Report (PR Newswire)
• Deal Prospectors — Dental Practice Valuation: EBITDA Multiples by Size (2026)
• Auxo Capital Advisors — Dental Practice Valuation Multiples: 2026 Guide
• Deal Prospectors — DSO Acquisition Offers: What Dentists Get Paid in 2026
• Scott Leune — DSO Acquisition Valuation Framework (2026)
• Dental Wealth Partners — DSO Deal Structures & Buyout Models Explained
• Specialty1 Partners — Joint-venture growth model
• Dental Transitions — DSO Dental Practice Transition Timeline (2026)
• Dental Transitions — Dental Practice Sale Multiples: 2026 Valuation Guide
• Dental Practice Insider — Buying or Selling a Dental Practice in 2026
• Hendershot Cowart P.C. — Dental Support Organizations and the corporate practice of dentistry
• Sidley Austin — California SB 351 corporate practice restrictions (Oct 2025)
• Rapp & Krock — Ownership of a dental practice in Texas
• DDS Lawyers — Colorado enacts stricter DSO regulations
• Warburg Pincus — MB2 Dental recapitalization (Nov 2024)
• Gryphon Investors — Gryphon Investors acquires Smile Brands
• Group Dentistry Now — A Deeper Look at KKR's Investment in Heartland Dental
• Dental Practice Loan Guide — SBA loans for a dental practice
• Dental Practice Insider — Dental practice loans and financing (2026)
• Bay Street Lending — SBA loans for dental practice acquisition
• Fifth Third — Fifth Third completes acquisition of Provide (Aug 2021)
• Panacea Financial — Practice solutions
• Veritas Dental Resources — PPO fee negotiations (Sept 2025)
• Dentx — Dental hygiene production benchmarks

Related resources

• Dental due diligence checklist — the per-practice diligence screen: what to verify on each dental target before you sign
• DSO offer evaluation guide — the seller's read of the same deal structures: what the dentist across the table is evaluating
• DSO recapitalization data room guide — staging the exit: how to run the recap room and what a recap buyer expects
• Roll-up data room guide — the generic serial-acquisition room program: room-per-target architecture and the reusable add-on index
• Dental practice sale guide — the seller-side view: valuation, process, and exit paths for a practice owner
• Best dental M&A advisors — how to choose the advisor or broker who runs your acquisitions
• Healthcare due diligence — the generic healthcare DD framework that feeds the dental integration plan
• Independent sponsor healthcare capital — the deal-by-deal capital path for a healthcare consolidator